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Available online 21 September 2016Endothelial dysfunction is a hallmark of inﬂammatory conditions. We recently demonstrated that prostaglandin
(PG)E2 enhances the resistance of pulmonary endothelium in vitro and counteracts lipopolysaccharide (LPS)-in-
duced pulmonary inﬂammation in vivo via EP4 receptors. The aim of this study was to investigate the role of the
EP1/EP3 receptor agonist 17-phenyl-trinor-(pt)-PGE2 on acute lung inﬂammation in a mouse model. In LPS-in-
duced pulmonary inﬂammation inmice, 17-pt-PGE2 reduced neutrophil inﬁltration and inhibited vascular leak-
age. These effects were unaltered by an EP1 antagonist, but reversed by EP4 receptor antagonists. 17-pt-PGE2
increased the resistance of pulmonary microvascular endothelial cells and prevented thrombin-induced disrup-
tion of endothelial junctions. Again, these effects were not mediated via EP1 or EP3 but through activation of the
EP4 receptor, as demonstrated by the lack of effect ofmore selective EP1 and EP3 receptor agonists, prevention of
these effects by EP4 antagonists and EP4 receptor knock-down by siRNA. In contrast, the aggregation enhancing
effect of 17-pt-PGE2 in human platelets was mediated via EP3 receptors. Our results demonstrate that 17-pt-
PGE2 enhances the endothelial barrier in vitro on pulmonary microvascular endothelial cells, and accordingly
ameliorates the recruitment of neutrophils, via EP4 receptors in vivo. This suggests a beneﬁcial effect of 17-pt-
PGE2 on pulmonary inﬂammatory diseases.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Pulmonary inﬂammation1. Introduction
The vascular endothelium forms the barrier between blood circula-
tion and the interstitial space and regulates the exchange of plasma com-
ponents, adhesion and extravasation of leukocytes, and haemostasis [1].
During inﬂammatory processes endothelial leakage occurs resulting in
plasma extravasation and edema formation [2]. The integrity of the en-
dothelial barrier is tightly regulated by cell-to-cell contacts like adherent
and tight junctions between adjacent cells and connection to the actin
cytoskeleton [1,3,4]. Prostanoids and phospholipids such as sphingosin-
1-phosphate are involved in the regulation of endothelial barrier [5,6].andin E2; BAL, bronchoalveolar
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. This is an open access article underProstaglandin (PG)E2 is the most abundant prostanoid in humans [7]
and exerts a variety of biological functions through four different recep-
tors (EP1–4), which differ in tissue speciﬁc gene expression [8]. These re-
ceptors activate different signaling pathways: EP1 receptor binding leads
to an increase of intracellular Ca2+ levels, assumed of being coupled to a
Gαq-protein. EP2 and EP4 receptors induce cyclic AMP (cAMP) produc-
tion, whereas EP3 receptors couple to a Gαi-protein and inhibit cAMP
synthesis [9]. PGE2 is mainly regarded as a potent pro-inﬂammatory
mediator due to its effects on vasodilation, vascular permeability and
nociception [10]. However, the role of PGE2 in the regulation of im-
mune responses is more complex. Notably the lung represents a
privileged organ with regard to PGE2 actions [11]. In the airways,
PGE2 shows an anti-inﬂammatory mode of action as it was demon-
strated to inhibit the release of a number of cytokines and chemokines
via activation of the EP4 receptor [10–12] and inhibition of mast cell-
induced bronchoconstriction via the EP2 receptors [13]. However, EP1
and EP3 receptors play a minor role in regulation of inﬂammatory pro-
cesses in the lung [12]. PGE2 was shown to enhance the endothelial
barrier function of human pulmonary artery endothelial cells via PKA
and Epac/Rap activation leading to Rac activation and cytoskeletal re-
modeling [6]. We recently revealed that PGE2 promotes barrierthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(HMVEC-L) via EP4 receptor-induced strengthening of the junction
and reduces endothelial trafﬁcking of neutrophils [14]. Moreover, we
recently demonstrated that PGE2, via activation of the EP4 receptor,
also shows barrier promoting effects in vivo in a mouse model of lipo-
polysaccharide (LPS)-induced acute lung inﬂammation [15].
In this study we investigated the role 17-phenyl tinor (pt)-PGE2 on
endothelial barrier function and the underlying molecular mechanism
in HMVEC-Ls as well as in amurinemodel of LPS-induced acute pulmo-
nary inﬂammation. We found that 17-pt-PGE2 concentration-depen-
dently enhanced endothelial barrier function, whereas a more speciﬁc
EP1 receptor agonist ONO DI-004 [16] or the EP3 receptor agonist
sulprostone did not mimic this effect. Surprisingly, the effect induced
by 17-pt-PGE2 was mediated by the EP4 receptor and not by EP1 or
EP3 receptors. Furthermore, we show that 17-pt-PGE2 strengthens the
endothelial junctions of HMVEC-Ls and reduces stress ﬁber formation
upon treatment with thrombin. Conversely to our ﬁndings in endothe-
lial cells, 17-pt-PGE2 promotes platelet aggregation via EP3 receptors.
In a murine model of acute pulmonary inﬂammation, 17-pt-PGE2
caused a decrease in pulmonary extravasation and a reduction of inﬁl-
trating neutrophils, which was mediated by EP4 receptor activation.
Our results demonstrate that 17-pt-PGE2 - in addition to its de-
scribed effects on EP1 and EP3 receptors - also acts as an EP4 agonist
and thereby enhances vascular barrier function.
2. Materials and methods
2.1. Reagents
Laboratory chemicals were from Sigma-Aldrich (Vienna, Austria)
unless speciﬁed. The EP1 receptor agonist ONODI-004, the EP4 receptor
agonist ONO AE1-329 and the EP4 receptor antagonist ONO AE3-208
were kind gifts from ONO Pharmaceuticals (Osaka, Japan). PGE2, 17-
pt-PGE2, SC51089, GW627368X, L-161,982, ONO-8711, iloprost, and
isobutylmethylxanthine were from Cayman Chemical (Ann Arbor, MI,
USA). L-161,798 was purchased from Tocris Biosciences (Bristol, UK)
and SC51322 from Biomol (Hamburg, Germany). The VE-cadherin
mouse monoclonal antibody was obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA) and secondary ﬂuorescently-labeled antibod-
ies and Texas Red-X Phalloidin were purchased from Invitrogen
(Invitrogen, Lofer, Austria). Antibody diluent was from Dako (Glostrup,
Denmark), Ultra V Block from Fisher Scientiﬁc (Vienna, Austria).
Vectashield/DAPI mountingmediumwas obtained from Vector Labora-
tories (Vector Laboratories, Burlingam, CA, USA).
2.2. Animals
Male BALB/c mice, 6–8 week old (body weight 22–25 g), were ob-
tained from Charles River (Sulzfeld, Germany). Mice were housed in in-
dividually ventilated cages (4 per cage) under controlled conditions of
temperature (set point 21 °C), air humidity (set point 50%) and a 12 h
light/dark cycle (lights on at 6:00 a.m.) and habituated to the environ-
ment for at least one week. Standard chow and water was provided
ad libitum. Mice were randomly assigned before treatment. The exper-
imental procedure used in this studywas approved by the Austrian Fed-
eral Ministry of Science, Research and Economy (BMWF 66.010/032-II/
10b/2012 and BMWF66.010/0094_II/3b/2013) and performed in accor-
dance with the European Communities Council Directive of 24 Novem-
ber 1986 (86/609/EEC) and comply with the ARRIVE guidelines [17].
Experiments were performed as humanely as possible to minimize all
suffering.
2.3. LPS-induced acute pulmonary inﬂammation
Pulmonary inﬂammation was induced as described [15]. Brieﬂy,
mice were slightly anaesthetized with ketamine/xylazine (50 mg/5mg/kg i.p.). LPS (Escherichia coli O55:B5; 20 μg per mouse in 50 μL
PBS,) or vehicle or LPS in combination with 17-pt-PGE2 (20 μg per
mouse), the EP1 agonist ONO DI-004 (20 μg per mouse) or the respec-
tive vehicle were applied intranasally in a volume of 25 μL to each
snare. Pretreatment with the EP1 receptor antagonist SC51089 (25
mg/kg) [18] and the EP4 receptor antagonists ONO AE3-208 (10 mg/
kg) [19] and GW627368X (10 mg/kg) [20] was performed subcutane-
ously, 30 min prior to intranasal application. Mice were sacriﬁced 4 h
post intranasal treatment with an overdose of pentobarbital (100 mg/
kg i.p), followed by bronchoalveolar lavage (BAL) ﬂuid sampling as pre-
viously described [21]. Leukocytes in BAL ﬂuid were analyzed by ﬂow
cytometry as described below.
2.4. Leukocyte analysis by ﬂow cytometry
Leukocytes were analyzed as described [15]. Brieﬂy, BAL ﬂuid was
centrifuged at 400 ×g for 7 min at 4 °C. Following two washing steps
with Ca2+ and Mg2+ free PBS, cells were incubated for 30 min at 4 °C
with the following monoclonal antibodies: FITC-conjugated MHC-II PE
conjugated CCR3 AB, PE-Cy5.5 conjugated CD3e Ab PE-Cy7 conjugated
B220 Ab APC conjugated CD11c Ab and CD16 Block (all Ab from BD
Pharmingen). Samples were washed, ﬁxed and measured on a
FACSCalibur ﬂow cytometer.
2.5. Pulmonary vascular permeability
Mice were intranasally treated with LPS (20 μg per mouse), vehicle
or LPS in combination with 17-pt-PGE2 (20 μg or 60 μg per mouse)
and in additional experiments mice were pretreated with the EP4 an-
tagonist ONO AE3-208 (10 mg/kg) as described above and Evans blue
leakage was determined [15]. Brieﬂy, 3 h post treatment mice were
injected with Evans blue (60 mg/kg in saline) in the tail vein, 1 h later
mice were sacriﬁced with pentobarbital (100 mg/kg, i.p) and exsangui-
nated by cutting the abdominal aorta. The lungs were perfused via the
right ventricle with 10 mL of phosphate buffered saline (PBS) contain-
ing 5 mM EDTA. Thereafter lungs were excised and weighed, then ho-
mogenized and incubated with formamide (18 h, 60 °C). After
centrifugation (5000 ×g for 20 min) the absorbance at 620 nm and
740 nmwasmeasured. The Evans blue content of tissue was calculated
and corrected for the presence of heme pigments as described [22].
2.6. Culture of endothelial cells and electrical resistance measurements
HMVEC-Lwere purchased fromLonza (Verviers, Belgium) as tertiary
cultures andwere cultivated in EGM-2MVbullet kitmedia supplement-
ed with 5% FCS and cultivated as previously described [14]. For resis-
tance measurements cells were grown to conﬂuence on 1% gelatin-
coated polycarbonate biochips with gold microelectrodes (ECIS
8W10E+) for 48 h. Cells were serum starved for 1 h and endothelial re-
sistance was measured with an Electrical Cell-substrate Impedance
Sensing System (ECIS; Applied Biophysics, Troy, NY, USA), as described
[14]. 3–4 independent experiments were performed in duplicates.
2.7. Transfection of endothelial cells and real time RT-PCR
HMVEC-L were transfected with Lipofectamine RNAiMAX (Thermo
Fisher Scientiﬁc, Waltham, MA, USA) according to the manufacturer's
instructions. Brieﬂy, HMVEC-L were seeded in 6-well plates and
transfected when reaching 50–70% conﬂuence with PTGER4 FlexiTube
–GeneSolution siRNA or a non-targeting control siRNA (Qiagen, Hilden,
Germany). Knock-down of PTGER4 was achieved by application of
50 nM of speciﬁc PTGER4 siRNA. For relative quantiﬁcation of mRNA
real time PCR was performed (CDX Connect™ Real-Time PCR detection
systemwith CFXManager™ software 3.1 (Bio-Rad, Hercules, CA, USA)).
48 h after transfection, RNA isolation was performed using RNA easy kit
(Qiagen) and DNA removal was performed with Ambion DNA removal
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reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad) ac-
cording to the manufacturer's instruction. Real-time PCR was per-
formed using SsoAdvanced™ Universal SYBR® Green Supermix with
PrimePCR™ SYBR® Green Assay primers for PTGER4 or GAPDH,
human (both Bio-Rad) according manufacturer's instructions. Samples
were measured in triplicates and GAPDH was used as the reference
gene. Quantiﬁcation of mRNA expression relative to control siRNA
were calculated with the 2−ΔΔCT method and data are shown as per-
centage of control siRNA. For subsequent ECIS assays, transfected endo-
thelial cells were detached using trypsin/EDTA (Lonza, Verviers,
Belgium) pooled and equally divided to the ECIS array. Cells were cul-
tured overnight, and then the ECIS experiments were performed as de-
scribed above.2.8. VE-cadherin and F-actin staining
VE-cadherin and F-actin staining was performed as described previ-
ously [14]. Brieﬂy, HMVEC-L were grown on gelatin-coated chamber
slides for 2 days. When reaching conﬂuence, endothelial cells were in-
cubated with 17-pt-PGE2 or vehicle for 10 min followed by thrombin
stimulation for 15 min. Endothelial cells were ﬁxed with formaldehyde
and permeabilized using Triton-X-100 (0.1%), unspeciﬁc binding sites
were blocked with Ultra V blocking solution. Slides were incubated
with a speciﬁc VE-cadherin antibody (1 μg/mL) or isotype control anti-
body, followed by staining with Alexa Fluor 488-conjugated secondary
antibody (4 μg/mL) and Texas Red-X Phalloidin conjugate (5 U/mL).
Slidesweremountedwith Vectashield/DAPImountingmedium and im-
ages were taken utilizing the Olympus IX70 ﬂuorescence microscope
and an Olympus UPlanApo-60×/14.2 oil immersion lens.Fig. 1. 17-pt-PGE2 prevents LPS-induced neutrophil inﬁltration in BAL ﬂuid via EP4 receptors. BA
presence or absence of 17-pt-PGE2. Pretreatment of the mice with the (A) EP1 receptor antago
AE3; 10 mg/kg sc.) and GW627368X (GW; 10 mg/kg sc.). (C) Concomitant intranasal administ
using one-way ANOVA and multiple comparisons were calculated with Tukey post test. *p b 0
PGE2 = 9; & SC 25 mg = 3] [B: veh = 9, LPS = 11, LPS&17-pt-PGE2 = 12, & ONO AE3 = 10:2.9. Blood collection and washed platelet preparation
The study was approved by the Institutional Review Board (Ethics
committee of the Medical University Graz). Blood was drawn from
healthy volunteers after they signed an informed consent form. Whole
blood from healthy donors was collected using sodium citrate (3.8%)
as anticoagulant. To obtain washed platelet preparation, platelet rich
plasmawas prepared by centrifugation at 400×g for 20min. Thereafter,
the platelets were washed twice with a low pH buffer (140 mM NaCl,
10 mM NaHCO3, 2.5 mM KCl, 0.9 mM Na2HPO4, 2.1 mM MgCl2,
22 mM C6H5Na3O7, 0.055 mM glucose and 0.35% BSA, pH = 6.5) and
centrifuged for 15 min at 1000 ×g. The pellet was resuspended in
Tyrode buffer (10 mM HEPES, 134 mM NaCl, 1 mM CaCl2, 12 mM
NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2 and 0.055 mM
glucose, pH = 7.4). These washed platelets were used for functional
platelet assays.2.10. Platelet aggregation
Platelet aggregation was recorded at 37 °C with constant stirring
using the 4-channel platelet aggregometer APACT4004 (LABiTec,
Ahrensburg, Germany) as previously described [23–25]. Aggregation
of washed platelets was measured as the increase in light transmis-
sion for 6 min starting with the addition of the proaggregatory stim-
ulus collagen (1.25–5 μg/mL). 17-pt-PGE2 (10–1000 nM) was added
5min prior to platelet stimulation. In additional experiments the EP3
antagonist L-798,106 (75 nM) was added 10 min prior to agonist
treatment. Data were expressed as percent of maximum light trans-
mission, with non-stimulated washed platelets being 0% and Tyrode
buffer 100%.L ﬂuidwas collected 4 h after intranasal application of (A,B) LPS (20 μg) or vehicle (veh) in
nist SC51089 (SC; sc. 30 min before), or (B) with the EP4 antagonists ONO AE3-208 (ONO
ration of the EP1 agonist ONO DI-004 (20 μg) and LPS (20 μg) or veh. Data were analyzed
.05, ** p b 0.01, *** p b 0.001. Animals used per group: [A:veh = 5; LPS =5; LPS&17-pt-
& GW= 5][C: veh = 5; LPS = 6; ONO DI-004 = 6].
Fig. 2. 17-pt-PGE2 inhibits LPS-induced pulmonary vascular leakage. Evans blue (EB;
60 mg/kg) extravasation in the lung. Intranasal application of veh or LPS (20 μg) in
the presence or absence of 17-pt-PGE2 (20 or 60 μg) Data are shown as Evans Blue (EB)
mg/g wet weight and were analyzed using one-way ANOVA and multiple comparisons
were calculated with Tukey post test *p b 0.05, ***p b 0.001. Animals used per group:
[veh n= 5; LPS n= 6; LPS & 17-pt-PGE2 20 μg n = 5, 60 μg n = 6].
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All data are shown as mean + SEM for n observations. Statistical
analyses were performed using GraphPad Prism software 6.0 (La Jolla,
CA; USA) Experiments using endothelial cells were performed in dupli-
cates; electrical resistance-measurements were analyzed by two-way
ANOVA for repeated measurements. Groups were compared byFig. 3. 17-pt-PGE2 increases endothelial barrier function of human lungmicrovascular endothel
004 or (C) the EP3 receptor agonist sulprostone (concentrations as indicated). An arrow ind
resistance of 3–4 independent experiments performed in duplicates. Data were analyzed by t
with Dunett's post test. ***p b 0.001, compared to vehicle.Dunnett's or Tukey multiple comparison test; aggregation experiments
were analyzed with one-way ANOVA followed by Dunnett's or Tukey
multiple comparison test; the different treated groups of mice were
compared with one-way ANOVA followed by Tukey post-hoc test.
Data from EP4 receptor knock-down experiments were compared
with paired t-test. Probability values of p b 0.05 were regarded as statis-
tically signiﬁcant.3. Results
3.1. 17-pt-PGE2 inhibits LPS-induced neutrophil accumulation in the
murine lung via EP4 receptors
Acute pulmonary inﬂammation in mice was induced by the intrana-
sal application of LPS (20 μg), which caused a pronounced accumulation
of neutrophils in the BAL ﬂuid after 4 h. Co-administration of 17-pt-
PGE2 (20 μg) with LPS resulted in an inhibition of LPS-induced
neutrophilia in the airways (Fig. 1 A,B). In contrast, concomitant intra-
nasal application of LPS and the EP1 receptor agonist ONO DI-004
(20 μg), did not affect the recruitment of neutrophils into the BAL ﬂuid
(Fig. 1 C). To further investigate whether the EP1 or EP4 receptors me-
diate this effect, mice were pretreated with the EP1 receptor antagonist
SC51089 (25mg/kg) or the EP4 receptor antagonists ONO AE3-208 and
GW627368X (10 mg/kg, both). The EP1 and EP4 antagonists by them-
selves had no effect on the neutrophil inﬁltration (data not shown).
While the EP1 antagonist did not inﬂuence the inhibitory effect of 17-
pt-PGE2 (Fig. 1 A), the EP4 antagonists reversed the effect (Fig. 1 B), sug-
gesting that in the mouse model of LPS-induced acute pulmonaryial cells. HMVEC-L were treatedwith vehicle, (A) 17-pt-PGE2, (B) the EP1 agonist ONO DI-
icates start of treatment. Endothelial resistance is shown as mean + SEM of normalized
wo-way ANOVA for repeated measurements and multiple comparisons were calculated
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tion of the EP4 receptor.
3.2. 17-pt-PGE2 counteracts LPS-induced pulmonary vascular leakage
In addition to neutrophil inﬁltration, acute pulmonary inﬂammation
causes pulmonary vascular leakage. Intranasal administration of LPS
(20 μg) caused signiﬁcant pulmonary vascular leakage as determined
by Evans Blue extravasation, which was inhibited by co-application
with 17-pt-PGE2 (20 and 60 μg; Fig. 2). In a separate set of experiments,
mice were pretreated with the EP4 receptor antagonist ONO AE3-208
(10 mg/kg). Here we found that the EP4 receptor antagonist restored
the LPS-induced plasma extravasation (as statistically compared with
vehicle-treated mice) that was abrogated by 17-pt-PGE2 (20 μg) (Sup-
plementary Fig. S1). Therefore, EP4 receptor activation seems to be in-
volved in the inhibition by 17-pt-PGE2 of the LPS-induced pulmonary
vascular leakage, similar to its inhibitory effect on neutrophil accumula-
tion in the lung (Fig. 1).Fig. 4. The 17-pt-PGE2 induced endothelial barrier enhancement is mediated by EP4 receptors.
(A) SC51322 (1 μM) or (B) ONO-8711 (1 μM) (C) the EP3 antagonist L-798,106 (1 μM) or the E
indicated by arrowheads) before treatment with 17-pt-PGE2 or vehicle (100 nM; indicated b
independent experiments performed in duplicates. Data were analyzed by two-way ANOVA
test. **p b 0.01, ***p b 0.001, as compared to vehicle, ##p b 0.01, ###p b 0.001, as compared t3.3. The endothelial barrier-promoting effect of 17-pt-PGE2 is mediated by
EP4 receptors in vitro
As we observed a beneﬁcial effect of 17-pt-PGE2 regarding neutro-
phil inﬁltration and pulmonary vascular leakage in murine model of
acute pulmonary inﬂammation, we next investigated its effect on the
barrier function in vitro. 17-pt-PGE2 caused a signiﬁcant, concentra-
tion-dependent increase in the resistance of HMVEC-L monolayer,
which peaked at 40–60 min after application and showed a long lasting
effect of N3 h (Fig. 3A). In contrast, the selective EP1 agonist ONODI-004
and the EP3 agonist sulprostone had no effect on the resistance up to
concentrations of 1 μM (Fig. 3 B,C).
To further investigate which of the EP receptors is involved in the
barrier promotion by 17-pt-PGE2,we pretreatedHMVEC-Lwith the spe-
ciﬁc EP1 receptor antagonists SC51322 (1 μM) and ONO-8711 (1 μM)
and the EP3 antagonist L-161,982 (1 μM) 15 min before 17-pt-PGE2
(100 nM) application. Neither EP1 receptor antagonists signiﬁcantly re-
duced the effect of 17-pt-PGE2 (Fig. 4 A,B), conﬁrming the results weHMVEC-L grown on gold microelectrodes were pre-treated with EP1 receptor antagonist
P4 receptor antagonists (D) ONO AE3-208 (1 μM) or (E) L-161,982 (1 μM) for 15 min (as
y arrow). Endothelial resistance is shown as mean + SEM of normalized resistance of 3
for repeated measurements and multiple comparisons were calculated with Tukey post
o 17-pt-PGE2.
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not involved in the barrier enhancing effect. Since 17-pt-PGE2 is also
known to activate EP3 receptors,we testedwhether the barrier promot-
ing effect wasmediated via EP3 receptors [26]. However, pre-treatment
with the speciﬁc EP3 receptor antagonist did not counteract the effect of
17-pt-PGE2 (Fig. 4 C). Since we previously found that activation of the
EP4 receptor augments the endothelial resistance on HMVEC-Ls [14],
we pretreated cells with the EP4 antagonists ONO AE3–208 (1 μM)
and L-161,982 (1 μM), which totally abolished the effect of 17-pt-PGE2
(Fig. 4 D,E). Also in HUVECs, 17-pt-PGE2 increased resistance via EP4 re-
ceptor activation, but this effect was less pronounced (Supplementary
Fig. S2). We already demonstrated that HMVEC-L express EP1, EP3
and EP4 receptors, but lack EP2 receptors as determined by ﬂow cytom-
etry [14]. Herewe investigated themRNA expressionwith real-timeRT-
PCR and found mRNA of the EP4 receptor, and very low levels of EP1
mRNA as indicated by the higher delta CT values, but we could not de-
tect EP2 or EP3 receptor mRNA (supplementary Fig. S3A). EP2–4 recep-
tors were previously described to be present on peripheral blood
monocytes [27], hencewe usedmonocytes as positive control for EP re-
ceptor expression (supplementary Fig. S3B).
In order to conﬁrm our ﬁndings of 17-pt-PGE2 acting via EP4 recep-
tors we performed EP4 receptor knock-down in HMVEC-L using siRNA
approach. We found that silencing the EP4 receptors completely
abolished the barrier promoting effect of both 17-pt-PGE2 and the EP4
receptor agonist ONOAE1-329 (Fig. 5 A,B). Knock-down of EP4 receptor
was conﬁrmed using real time RT-PCR as shown in Fig. 5 C. Therefore,
our results unequivocally suggest that 17-pt-PGE2 acts as an EP4 recep-
tor agonist on HMVEC-Ls.
Finally, we addressed the involvement of cAMP in HMVEC-L, but
found no increase in cAMP production in response to 17-pt-PGE2,
whereas the IP receptor agonist iloprost (300 nM) and the adenylyl cy-
clase activator forskolin (20 μM) induced cAMP (Supplementary Fig.Fig. 5. Knock-down of EP4 receptors inhibits the barrier promoting effect of 17-pt-PGE2. Untr
microelectrodes and were either treated with (A) 17-pt-PGE2 (100 nM) or the (B) EP4 recep
as normalized mean + SEM of 3 independent experiments performed in duplicates. Data we
were calculated with Tukey post test. **p b 0.01, ***p b 0.001, as compared to control siRNA
transfected with non-silencing control siRNA or EP4 siRNA (50 nM each) and incubated for 4
experiments. Data were analyzed by paired t-test. **p b 0.01, as compared to control siRNA.S4). This was even more pronounced when cells were pretreated with
the phosphodiesterase inhibitor isobutylmethylxanthine (IMBX,
0.5 mM for 10 min; Supplementary Fig. S4). These results are in line
with ﬁndings that the barrier-enhancing effect mediated via EP4 recep-
tor activation does not depend on cAMP [14].
3.4. 17-pt-PGE2 protects endothelial junctional integrity
The integrity of the endothelial cell layer ismaintained by endothelial
adherens junctions connected to cytoskeletal ﬁlamentous-actin (F-actin)
network. We assessed the regulatory role of 17-pt-PGE2 on VE-cadherin
expression in the endothelial junctions and changes of F-actin polymer-
ization by using immunoﬂuorescence microscopy. Generally, vehicle-
treated cells showed intact adherens junction complexes between adja-
cent cells and peripheral F-actin polymerization. After 15 min treatment
with 17-pt-PGE2 (100 nM) VE-cadherin expression in the adherens
junctions appeared to be more intense and we observed a more pro-
nounced F-actin network in the paracellular regions. Treatment with
thrombin (0.5 U/mL) caused disruption of endothelial adherens junc-
tions, remodeling of the F-actin network into stress ﬁbers, and forma-
tion of paracellular gaps. This was prevented by the pretreatment
with 17-pt-PGE2 (Fig. 6).
3.5. 17-pt-PGE2 potentiates collagen-induced platelet aggregation via the
EP3 receptor
Platelets have been implicated in inﬂammatory reactions [28–30]
and we have described that EP4 receptors confer inhibition of platelet
aggregation and activation [23]. Since we were able to show that 17-
pt-PGE2 acts as an EP4 receptor agonist in human pulmonary endothe-
lial cells, we hypothesized that this may be true for other cell types as
well. Washed platelets were treated with 17-pt-PGE2 (10, 100,ansfected, control siRNA or EP4 siRNA transfected endothelial cells were grown on gold
tor agonist ONO AE1-329 (100 nM; indicated by arrow). Endothelial resistance is shown
re analyzed by two-way ANOVA for repeated measurements and multiple comparisons
. EP4 receptor knock-down was conﬁrmed with real time RT-PCR (C). HMVEC-L were
8 h. EP4 receptor expression is shown as percentage of control siRNA of 3 independent
Fig. 6. 17-pt-PGE2 prevents the thrombin-induced disruption of endothelial junctions. HMVEC-L was cultured in chamber slides until they reached conﬂuence. Cells were pre-incubated
with 17-pt-PGE2 (100 nM) for 10min followed by exposure to vehicle or thrombin (0.5U/mL, 15min) and then stainedwith anti-VE-cadherin antibody (green) or phalloidin-Texas Red-X
conjugate (red) andDAPI (blue). Pictureswere takenwith anOlympus IX70 ﬂuorescencemicroscope andOlympusUPlanApo-60×/14.2 oil immersion objective. Images are representative
of 3 independent experiments.
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collagen (1.25 to 10 μg/mL) was adjusted to cause submaximal aggrega-
tion as previously described [23–25]. We found that 17-pt-PGE2 in-
creased the collagen-induced aggregation of washed platelets, which
was signiﬁcantly different from vehicle-treated platelets at 1 μM of the
prostaglandin (p b 0.01) (Fig. 7 A). Pretreatment with the highly potent
EP3 receptor antagonist L-798,106 (75 nM) 10 min prior to 17-pt-PGE2
(1 μM) counteracted the enhancement of collagen-induced aggregation,
demonstrating the involvement of EP3 receptors (Fig. 7 B, C). 17-pt-PGE2
did not impact Ca2+ ﬂux in human platelets alone and did not inﬂuence
the Ca2+-inducing effect of ADP. The same was observed with the EP3
receptor agonist sulprostone (data not shown). To investigate whether
a high concentration of 17-pt-PGE (10 μM) causes an inhibition of stim-
ulus-induced aggregation, which may be due to activation of the EP4 re-
ceptor, collagen was used at a concentration that caused about 70–80%
aggregation. However, under these conditionswe could not detect an in-
hibitory effect on platelet aggregation (n= 3, data not shown).
4. Discussion
In this study we demonstrate that the purported EP1/EP3 receptor
agonist 17-pt-PGE2 concentration-dependently increases the endotheli-
al barrier function of HMVEC-L as determined by an increase in electri-
cal resistance, and protects against thrombin-induced disruption ofendothelial junctions and stress ﬁber formation. These effects were
comparable to PGE2 [14]. Interestingly, the more speciﬁc EP1 receptor
agonist, ONO DI-004 and the EP3 receptor agonist sulprostone failed
to mimic this effect. The lack of involvement of EP1 and EP3 receptors
was conﬁrmed by EP1 and EP3 antagonists. In contrast, the barrier-
strengthening effect of 17-pt-PGE2 was reversed by EP4 antagonists as
well as by silencing of the EP4 receptor. Monolayers of endothelial
cells are accomplished by junctional structures, where VE-cadherin
plays a major role in adherens junction formation. We found a protec-
tive effect of 17-pt-PGE2 on thrombin-induced disruption of the
endothelial junctions and stress ﬁber formation, which was recently
demonstrated to bemediated via EP4 receptor activation [14]. Strength-
ening of vascular barrier function in vitro was shown for PGI2 and PGE2
via cAMPmediated activation of PKA-, Epac/Rap1- and Tiam1/Vav2-de-
pendent pathways of Rac1 activation [6]. Recently, we demonstrated
that EP4 receptor activation is responsible for the barrier-enhancing
effect of PGE2, which was independent of cAMP/PKA, PKC, NO or Rac
signaling but was mediated by cytoskeletal rearrangements [14]. This
is in line with our ﬁndings, as 17-pt-PGE2 did not induce cAMP synthe-
sis in HMVEC-L. In addition, wound healing was facilitated by EP4 re-
ceptor activation but was not inﬂuenced by EP2 and EP1/3 agonists
[14]. Here we demonstrate that the barrier enhancing effect or 17-
pt-PGE2 is mediated solely by EP4 but not by EP1 or EP3 receptor
activation.
Fig. 7. 17-pt-PGE2 augments collagen-induced aggregation in washed platelets via EP3 receptor activation. Platelet aggregation was induced by collagen, the concentrations (1.25–5 μg/mL)
were adjusted to give a submaximal, 20–40% aggregation. (A) Freshly preparedwashed plateletswere pretreatedwith 17-pt-PGE2 (10–1000 nM) for 5min, before stimulationwith collagen.
(B) Pre-treatment of platelets with the EP3 antagonist L-798,106 (75 nM) 10 min before addition of 17-pt-PGE2. (C) Original tracing showing that the proaggregatory effect of 17-pt-PGE2
(1000 nM) is inhibited by the EP3 receptor antagonist L-798,106. Results are shown asmean+ SEM of n=3–4 independent experiments and are normalized to the respective vehicle. Data
were analyzed using one-way ANOVA and multiple comparisons were calculated with Tukey post test *P b 0.05, **P b 0.01, as compared to vehicle.
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dissociation of cell-cell junctions, leading to plasma extravasation and
inﬁltration of inﬂammatory cells. Our second main ﬁnding was that in
a murine model of LPS-induced acute lung inﬂammation, 17-pt-PGE2
reduced pulmonary plasma extravasation and ameliorated the recruit-
ment of neutrophils into the BAL ﬂuid, which account as characteristic
clinical complications of acute lung injury [31]. This effectwasmediated
by EP4 receptor activation, which is in agreementwith our in vitro ﬁnd-
ings on the barrier function. PGE2 is well known to reduce the accumu-
lation of neutrophils within the BAL ﬂuid in LPS-induced acute lung
inﬂammation [32,33]. We showed recently that the effect of PGE2 on
LPS-induced neutrophil inﬁltration and LPS- as well as oleic acid-in-
duced plasma extravasation is mediated mainly via activation of the
EP4 receptor [15]. In addition it was demonstrated in EP4-, but not in
EP1-, EP2- and EP3-deﬁcient mice that only the EP4 receptor seems to
be responsible for the anti-inﬂammatory activity in mouse models of
lung inﬂammation [12].
The action of 17-pt-PGE2 as an EP1 receptor agonist [34] was dem-
onstrated in several experimental settings, including cancer, neurons,
vascular system, kidney andwas conﬁrmed by application of EP1 recep-
tor selective antagonists [35–41]. Receptor binding studies in human
and rat EP4 receptor-expressing systems support our ﬁndings that 17-
pt-PGE2 also can act as an EP4 receptor agonist [42–44], whilst opposing
ﬁndings are published for a murine EP4 receptor expressing system
[26]. In addition it was shown that 17-pt-PGE2 activates human as
well as murine and guinea pig EP3 receptors [26,34].
With regard to platelets, 17-pt-PGE2 has been described as aggrega-
tion-potentiating substance in human platelets [45]. Since it is known
that EP3 receptor activation is responsible for enhancing stimulus-in-
duced aggregation in human platelets [46–48] we investigated thepossible involvement of EP3 receptor. It is well established that prosta-
glandins have a biphasic effect on platelet aggregation,where activation
of the EP3 receptor has pro-aggregatory and activation of the EP4 recep-
tor anti-aggregatory effects [23,24]. Here we show that the pro-
aggregatory effect of 17-pt-PGE2 is mediated via EP3 receptor activa-
tion. In this model, we did not ﬁnd an involvement of the EP4 receptor,
as even high concentration of 17-pt-PGE2 (10 μM) was not capable of
inhibiting aggregation induced by collagen.
EP1, EP3 and EP4 receptor expression on HMVEC-L was shown re-
cently by ﬂow cytometry [14]. However, only EP4 mRNA expression
was previously described in these cells [49]. Our data obtained with
RT-PCR showed EP4 mRNA and very low levels of EP1 mRNA, but no
EP2 and EP3 mRNA expression was detectable in HMVEC-L. Although
EP1 receptor mRNA was detected, the effects of the purported EP1/
EP3 receptor agonist 17-pt-PGE2 on human pulmonary microvascular
endothelial cells were exclusively mediated via EP4 receptor activation.
In contrast, 17-pt-PGE2 acted on human isolated platelets as an EP3 re-
ceptor agonist. The preferential activation of EP4 receptors rather than
EP3 receptors can be explained by the lack of EP3 receptor expression
and comparatively low amount of EP1 receptors on HMVEC-L.
5. Conclusion
In conclusion, our results provide evidence that the purported EP1/
EP3 receptor agonist 17-pt-PGE2 possesses anti-inﬂammatory proper-
ties, promotes microvascular endothelial barrier function in vitro and
further abates neutrophil recruitment and plasma extravasation in a
murine model of pulmonary inﬂammation. Our data suggest that
these effects are mediated by EP4 receptor activation and that its
mode of action might be tissue and cell speciﬁc. We show here for the
188 A. Theiler et al. / Vascular Pharmacology 87 (2016) 180–189ﬁrst time that 17-pt-PGE2 exerts a beneﬁcial effect on pulmonary
inﬂammatory diseases.
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